Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
Public ClinicalTrials.gov record NCT02494024. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
Study identification
- NCT ID
- NCT02494024
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- C2N Diagnostics
- Industry
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Interventions
- Single dose C2N-8E12 Drug
- Single dose placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2015
- Primary completion
- Jul 31, 2016
- Completion
- Jul 31, 2016
- Last update posted
- Jul 25, 2017
2015 – 2016
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| University of California, Los Angeles (UCLA) | Los Angeles | California | 90095 | — |
| UCSD Department of Neurosciences | San Diego | California | 92037 | — |
| University of California, San Francisco | San Francisco | California | 94158 | — |
| University of Florida College of Medicine | Gainesville | Florida | 32607 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Indiana University Medical Center | Indianapolis | Indiana | 46202 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Columbia University | New York | New York | 10032-3795 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-2551 | — |
| Texas Health Presbyterian Dallas | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02494024, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 25, 2017 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02494024 live on ClinicalTrials.gov.